Candida auris is a yeast species first isolated from the external ear canal of a patient in Japan in 2009. Since then C. auris has been associated with a wide range of clinical infections, including bloodstream, wound and ear infections, in many countries globally. It has caused prolonged outbreaks on five continents including India, Pakistan, Venezuela, Colombia, Spain. Israel, South Africa and USA.
Commonly C. auris is resistant to the first-line antifungal drug fluconazole and this species can rapidly evolve to develop resistance, so specific antifungal susceptibility testing is indicated.
In UK laboratories, Candida species isolated from superficial sites are not routinely identified to species level or tested for antifungal susceptibility. Even if species identification is undertaken, isolates can be misidentified by some commercial kits.